Tune in on Sept. 24 for a live virtual conversation led by STAT's Ed Silverman exploring what's next for biosimilars.
The first big wave of biosimilars has arrived, with more lower-cost alternatives on the way. But as the market evolves, shifting policies and a complex health care system could disrupt recent progress.
Bring your questions and join the live conversation about the future of biosimilars and the forces shaping the market.
%20MH%20Testing/Larger%20Header%20Logos/STAT_Events2.png?height=88&upscale=true&name=STAT_Events2.png){kind=small}
.png?width=1200&upscale=true&name=924_Samsung_VirtualEvent_Marketing_EmailTall%20(1).png)
%20MH%20Testing/Footer%20Icons/Flipboard-logo.png?width=60&height=60&upscale=true&name=Flipboard-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/X-logo.png?width=60&height=60&upscale=true&name=X-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Linkedin-logo.png?width=60&height=60&upscale=true&name=Linkedin-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Facebook-logo.png?width=60&height=60&upscale=true&name=Facebook-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Youtube-logo.png?width=60&height=60&upscale=true&name=Youtube-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Instagram-logo.png?width=60&height=60&upscale=true&name=Instagram-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Threads-logo.png?width=60&height=60&upscale=true&name=Threads-logo.png){kind=logo}